ahk-cu peptide injection - Research Compound AHK-Cu - Ion Peptide

The compound is a quinolinium-class structure (5-amino-1-methylquinolinium) developed as a membrane-permeable selective inhibitor of the nicotinamide N-methyltransferase enzyme

You're iron or folic acid deficient

Why Researchers Choose PSPeptides US Manufactured: Every batch is synthesized in FDA-registered US facilities with strict QC oversight and documentation

Typical schedule is weekly for the first month, then every 24 weeks based on how you respond and your B12 levels

When to Adjust Dosing Increase dose if: After 4-6 weeks at current dose, no measurable body composition changes occur, youre tolerating current dose without side effects, youre below the upper clinical range (1 mg daily), and your physician approves escalation based on comprehensive assessment

The systemic effects of growth hormone secretagogues differ substantially from the targeted local effects of topically applied AHK-Cu